Liapis, Vasilios http://orcid.org/0000-0002-2354-3521
Tieu, William http://orcid.org/0000-0002-7161-4152
Wittwer, Nicole L. http://orcid.org/0000-0002-2331-5799
Gargett, Tessa http://orcid.org/0000-0003-3713-1373
Evdokiou, Andreas http://orcid.org/0000-0001-8321-9806
Takhar, Prab
Rudd, Stacey E. http://orcid.org/0000-0001-9996-8561
Donnelly, Paul S. http://orcid.org/0000-0001-5373-0080
Brown, Michael P. http://orcid.org/0000-0002-5796-1932
Staudacher, Alexander H. http://orcid.org/0000-0001-5034-9532
Funding for this research was provided by:
National Health and Medical Research Council (1126304)
Ray and Shirl Norman Cancer Research Trust
Royal Adelaide Hospital (12872)
Article History
Received: 4 March 2021
Revised: 28 April 2021
Accepted: 26 May 2021
First Online: 6 July 2021
Change Date: 11 August 2021
Change Type: Update
Change Details: This article was updated to amend the Acknowledgments.
Change Date: 16 August 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11307-021-01640-x
Declarations
:
: MPB is co-inventor on APOMAB® patents owned by AusHealth Research Pty Ltd. SER and PSD are listed as inventors on intellectual property relating to DFO-Sq that has been licensed from the University of Melbourne to Telix Pharmaceuticals. No other competing interests relevant to this article exist.